A 58-year-old woman presented to our emergency department with painful ulcers on the right side of her neck and on her left elbow. The ulcers, which had begun after minimal trauma, had increased in ...

Nepal: Pyoderma gangrenosum (PG) can occur without associated systemic disease and may resemble infectious or vascular ulcers ...

Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...

Pyoderma gangrenosum was first described as an extraintestinal manifestation of inflammatory bowel disease (IBD) by Brunsting and colleagues in 1930. 1 They described painful enlarging necrotic ulcers ...

Pyoderma gangrenosum (PG) is a rare, ulcerative skin condition of unknown origin, with an annual incidence of 3 to 10 cases per million people. Skin lesions develop as painful, edematous nodules or ...

Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...

A 2-point improvement in pain based on a numeric rating scale may indicate that patients are responding to treatment for pyoderma gangrenosum. To help determine whether a patient with pyoderma ...

Dear Dr. Roach: I am a 74-year-old woman who is in good health. I was diagnosed with pyoderma gangrenosum on my left leg and I was in a lot of pain. Can you tell me the cause of this rare disease?

Pyoderma gangrenosum (PG) is a rare, noninfectious neutrophilic dermatosis. Clinically, it begins with sterile pustules that rapidly progress into painful ulcers of variable depth and size with ...

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...

Our 36-year-old daughter-in-law is suffering from very painful pyoderma gangrenosum. Her latest outbreak followed a mosquito bite in September, and she is being treated as an outpatient. She also ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...